QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ALNY

QT65Alnylam Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
278.09
-4.63-1.64%
OverviewShort InterestFilings
ALNYQT65Alnylam Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
278.09-1.64%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89RPRX-1.38%$52.96
Snapshot
Index-P/E65.09EPS (ttm)
4.21
Insider Own0.27%
Shs Outstand133.51M
Perf Week-3.90%
Market Cap37.75BForward P/E26.07EPS next Y10.67Insider Trans-0.02%Shs Float-Perf Month-5.51%
Enterprise Value37.31BPEG0.03EPS next Q1.63Inst Own-Short Float-Perf Quarter-10.61%
Income581.30MP/S8.81EPS this Y78.01%Inst Trans-Short Ratio-Perf Half Y-28.91%
Sales4.29BP/B34.94EPS next Y42.34%ROA11.25%Short Interest-Perf YTD-30.07%
Book/sh8.05P/C52.70EPS next 5Y27.02%ROE98.29%52W High495.53 -43.88%Perf Year-9.92%
Cash/sh22.54P/FCF58.86EPS past 3/5Y-ROIC19.66%52W Low273.12 1.82%Perf 3Y-
Dividend Est.-EV/EBITDA40.36Sales past 3/5Y53.00% 49.76%Gross Margin80.89%Volatility2.21% 2.28%Perf 5Y-
Dividend TTM-EV/Sales8.70EPS Y/Y TTM354.59%Oper. Margin17.54%ATR (14)10.22Perf 10Y-
Dividend Ex-Date-Quick Ratio3.06Sales Y/Y TTM90.70%Profit Margin13.46%RSI (14)38.70Recom2.32
Dividend Gr. 3/5Y-Current Ratio3.13EPS Q/Q-SMA20-5.10%Beta0.59Target Price454.27
Payout0.00%Debt/Eq1.18Sales Q/Q96.46%SMA50-7.47%Rel Volume1.94Prev Close282.72
Employees2,230LT Debt/Eq1.56EarningsJul 30SMA200-25.72%Avg Volume1.11MPrice278.09
IPO DateJun 01, 2004Option/ShortYes / YesEPS/Sales Surpr.73.17% 4.57%Net Debt/EBITDA-0.47Volume2,155,140Change-1.64%
Analyst Ratings
DateActionAnalystRatingTarget
May-01-26ReiteratedMorgan StanleyEqual Weight$360 → $370
May-01-26ReiteratedBernsteinOutperform$448 → $447
Mar-16-26DowngradeJefferiesBuy → Hold
Feb-17-26ReiteratedCanaccord GenuityBuy$336 → $429
Feb-17-26UpgradeFreedom BrokerHold → Buy
Feb-17-26UpgradeFreedom Capital MarketsHold → Buy
Feb-13-26ReiteratedMorgan StanleyEqual Weight$408 → $360
Feb-13-26ReiteratedBernsteinOutperform$491 → $451
Feb-13-26ReiteratedChardan CapitalBuy$475 → $425
Feb-12-26ReiteratedStifel NicolausBuy$508 → $444
Latest News
Jun-14-26
Jun-14-2604:11PM
Alnylam Taps Generative AI And Nordic Expansion As Market Lags TargetsYahoo
Jun-12-26
Jun-12-2601:20PM
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?Yahoo
01:00PM
Alnylam to Host Tenth "RNAi Roundtable" Webcast SeriesYahoo
08:10AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Growth and a Key Technical SetupChartMill
Jun-10-26
Jun-10-2612:02PM
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic DevelopmentYahoo
12:02PM
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic DevelopmentYahoo
11:47AM
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic RegionYahoo
11:47AM
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic RegionYahoo
07:49AM
GENESIS Pharma Expands Collaboration With Alnylam Pharmaceuticals To Tap Four Nordic MarketsBenzinga
07:49AM
GENESIS Pharma Expands Collaboration With Alnylam Pharmaceuticals To Tap Four Nordic MarketsBenzinga
Jun-09-26
Jun-09-2608:22PM
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
05:03PM
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline ReadoutsYahoo
Jun-08-26
Jun-08-2609:06PM
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500Yahoo
09:06PM
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500Yahoo
11:00AM
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical OfficerYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,2873,7142,248
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A819677323
Gross Profit3,4683,0371,925
Selling, General and Administrative Excl. Other1,2931,211976
Research and Development1,4201,3241,126
Other Operating Expense300
Operating Income753502-177
Interest Expense282253142
Unusual Expense
———
Non-Operating Income (Expense)-117-7459
Net Income Before Taxes587323-377
Income Taxes-229-99
Consolidated Net Income577314-278
Net Income From Continuing Operations608314-278
Net Income577314-278
EPS (Recurring)4.362.39-2.18
EPS (Basic, Before Extraordinaries)4.362.39-2.18
EPS (Diluted)4.212.33-2.18
EBITDA924631-179
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio66.05170.67—
Price To Sales Ratio8.6314.03—
Gross Margin80.9081.7785.63
Operating Margin17.5613.52-7.87
Net Margin13.468.45-12.37
Shares Outstanding133131128
Market Capitalization36,98652,092—
Operating Lease Expense
———
Insider Trading Volume
$302.10$264.17$226.24$188.30$150.37● Close Price0.00M4.27M8.55M12.82M17.10MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PYOTT DAVID E IDirectorJun 01 '26Sale299.183,8301,145,8521,582Jun 03 12:00 AM
PYOTT DAVID E IDirectorJun 01 '26Option Exercise35.107,660268,8665,412Jun 03 12:00 AM
SCHULMAN AMY WDirectorMay 13 '26Option Exercise70.2022,5001,579,50023,211May 14 12:00 AM
McLaughlin MelissaChief Human Resources OfficerApr 06 '26Sale330.422,286755,3299,443Apr 07 12:00 AM
McLaughlin MelissaChief Human Resources OfficerApr 02 '26Sale319.591,624519,01411,729Apr 07 12:00 AM
Fitzgerald Kevin JosephCSO & EVP, Head of ResearchMar 05 '26Sale323.98658213,17720,569Mar 06 12:00 AM
Garg PushkalEVP Chief R&DMar 05 '26Sale323.962,404778,81218,693Mar 06 12:00 AM
Fitzgerald Kevin JosephCSO & EVP, Head of ResearchMar 04 '26Sale323.08633204,50821,227Mar 06 12:00 AM
Garg PushkalEVP Chief R&DMar 04 '26Sale323.082,309745,98321,097Mar 06 12:00 AM
Greenstreet YvonneChief Executive OfficerMar 04 '26Sale323.082,933947,58195,695Mar 06 12:00 AM
Poulton Jeffrey V.EVP, Chief Financial OfficerMar 04 '26Sale323.082,468797,34961,805Mar 06 12:00 AM
Tanguler TolgaEVP, Chief Commercial OfficerMar 04 '26Sale323.082,309745,98334,297Mar 06 12:00 AM
Fitzgerald Kevin JosephCSO & EVP, Head of ResearchMar 03 '26Sale319.731,652528,18921,860Mar 04 12:00 AM
Garg PushkalEVP Chief R&DMar 03 '26Sale319.741,775567,54723,406Mar 04 12:00 AM
Garg PushkalEVP Chief R&DMar 02 '26Sale327.661,717562,58625,181Mar 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR